Literature DB >> 8512266

Difficulties in endoscopic removal of Teflon granulomas of the vocal fold.

R H Ossoff1, M J Koriwchak, J L Netterville, J A Duncavage.   

Abstract

The difficulties in treating granulomas resulting from Teflon injection into the vocal fold are underreported in the literature. We have reviewed our experience with nine patients undergoing 27 procedures for Teflon granuloma. Two patients required tracheotomy before undergoing endoscopic granuloma removal because of airway compromise, and a third required urgent tracheotomy following endoscopy. One of the patients requiring elective tracheotomy had a granuloma that extended across the midline to the contralateral arytenoid, causing its fixation. Arytenoidectomy was required for decannulation in this patient. In all but one patient the granuloma nearly completely replaced the thyroarytenoid muscle. This extensive involvement often precludes the adequate excision of the granuloma in a single procedure; however, the microflap technique allows mucosal preservation to facilitate future procedures. In some cases the granuloma destroys large amounts of mucosa, and a microflap cannot be elevated and saved. The difficulties of excision are related to the near-total replacement of the thyroarytenoid muscle by granuloma. This paper will help the otolaryngologist--head and neck surgeon understand this destructive process and the resulting difficulties in surgical rehabilitation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8512266     DOI: 10.1177/000348949310200601

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  2 in total

1.  XeCl laser ablation of biocompatible PTFE studied by photothermal beam deflection.

Authors:  C D Skordoulis; M I Makropoulou; A L Bolovinos; A A Serafetinides
Journal:  Lasers Med Sci       Date:  1997-12       Impact factor: 3.161

2.  Lateral thyrotomy with strap muscle transposition for Teflon granuloma.

Authors:  Ming-Wang Hsiung; Yu-Liang Lin
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-09-11       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.